Testing Implementation Strategies to Improve Delivery of PrEP for Pregnant and Postpartum Women in Kenya

NCT ID: NCT05482360

Last Updated: 2025-02-26

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5173 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-01-01

Study Completion Date

2023-12-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests strategies for improving PrEP implementation in maternal and child health clinics using an interrupted time series.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aims to improve integrated delivery of PrEP to women seeking health services in maternal and child health clinics by piloting and evaluating four strategies or bundles of strategies for optimized PrEP delivery. Strategies to be tested include three packages of strategies identified by stakeholders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Exposure Prophylaxis HIV Infections Pregnancy Related

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

A difference-in-difference design will be used; this is a quasi-experimental design that compares data before an intervention is introduced to data after the intervention is introduced and compares that with the expected change before and after in comparison clinics. Three rounds of difference-in-differences tests will be used to evaluate three PrEP optimization interventions, identified by stakeholders based on qualitative information. Each of the three rounds will include 4 facilities receiving the intervention and 4 facilities serving as an ongoing concurrent comparator group; these 4 facilities will not receive any of the packages of interventions, but will undergo the same data collection procedures.
Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Package 1

Package 1: Three implementation strategies including fast tracking, provider re-training, and dispensing PrEP in MCH

Group Type EXPERIMENTAL

PrEP Optimization Interventions

Intervention Type OTHER

There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders

Comparator for Package 1

4 facilities were assigned to the comparator group and never received any implementation strategy.

Group Type NO_INTERVENTION

No interventions assigned to this group

Package 2

Package 2: Three implementation strategies including task shifting PrEP counseling from clinicians/nurses to HIV testing services providers (HTS), training different cadres, and dispensing PrEP in MCH

Group Type EXPERIMENTAL

PrEP Optimization Interventions

Intervention Type OTHER

There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders

Package 3

Package 3: Three implementation strategies including use of PrEP educational materials, PrEP health talks in waiting bays and dispensing PrEP in MCH

Group Type EXPERIMENTAL

PrEP Optimization Interventions

Intervention Type OTHER

There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders

Comparison for Package 2

4 facilities were assigned to the comparator group and never received any implementation strategy.

Group Type NO_INTERVENTION

No interventions assigned to this group

Comparison for Package 3

4 facilities were assigned to the comparator group and never received any implementation strategy.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PrEP Optimization Interventions

There were three bundles of strategies tested determined based on the qualitative information gathered in Aim 1 by stakeholders

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women receiving Maternal and Child Health (MCH) services HCW participating in satisfaction surveys

Exclusion Criteria

* Unwilling or unable to provide informed consent
Minimum Eligible Age

15 Years

Maximum Eligible Age

100 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

University of Washington

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Anjuli Wagner

Assistant Professor, Global Health

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anjuli Wagner, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Washington

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ober Health Center

Homa Bay, , Kenya

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kenya

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

K01MH121124

Identifier Type: NIH

Identifier Source: secondary_id

View Link

STUDY00008392-A

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.